Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Innovative Cellular Therapeutics

Request full access

A Shanghai-based biotechnology company engaged in research and development of cell therapy

Rockville, United StatesFounded 2009Biotech & Life Sciences

About Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology firm focused on developing cellular immunotherapies for solid tumors. The company was co-founded in 2009 by Dr. Larry (Lei) Xiao, who serves as Chairman, CEO, and CSO, and Dr. Zoe Zhao Wu, who is the President. Dr. Xiao brings over two decades of experience in stem cells, cell therapy, and gene editing, with a Ph.D. from Munich University and postdoctoral work at Johns Hopkins. His academic career includes professorships where he specialized in stem cell research, providing a strong scientific foundation for ICT's endeavors.

The company initially focused on induced pluripotent stem cells (iPSC) before pivoting to CAR-T cell technology. A significant milestone was achieved in 2015 when its first CAR-T product for Acute Lymphoblastic Leukemia demonstrated an 85% complete response rate in a 39-patient trial. This early success in liquid tumors informed the development of its solid tumor platform. By 2018, ICT established U.S. operations, opening its global headquarters in Rockville, MD, in 2019 to concentrate on the American market. As a venture-backed entity, ICT has successfully raised capital to advance its pipeline, with investors including CDH, LH Ventures, and SB China Venture Capital.

ICT's business model is centered on the research, development, and eventual commercialization of its CAR-T therapies. The company is currently pre-revenue, investing its capital into clinical trials to gain regulatory approval. The core of its therapeutic strategy is the proprietary CoupledCAR® technology platform. This platform is engineered to overcome the challenges of treating solid tumors by promoting the expansion and persistence of CAR-T cells within the body, enhancing their ability to infiltrate tumors and resist the immunosuppressive tumor microenvironment. This enables the engineered T-cells to effectively target and kill cancer cells.

The lead product candidate, GCC19CART, targets relapsed or refractory metastatic colorectal cancer (mCRC). Clinical trials for GCC19CART have shown promising results in both the U.S. and China. In a U.S. Phase 1 trial, an objective response rate of 80% was observed at a specific dosage level. The U.S. FDA granted Fast Track designation to GCC19CART in April 2022, potentially accelerating its path to market. Beyond colorectal cancer, ICT is advancing a pipeline of other CAR-T candidates for solid tumors, including thyroid and prostate cancer.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2009
Headquarters
Rockville, United States
Employees
15
Open positions
None listed
Dealroom signal
46.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Market Intelligence, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Sep 2021 $40M $160M CDH Investments —
SERIES COther financing Dec 2019 $0 — Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Innovative Cellular Therapeutics website traffic

Latest recorded traffic for Innovative Cellular Therapeutics is 3.4K monthly website visits, up 161.5% over the last three months. Innovative Cellular Therapeutics's team grew 15.4% over the past year.

Latest monthly visits3.4K 3-month web change+161.5% 1-year team growth+15.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Innovative Cellular Therapeutics in the Rockville ecosystem

Live from Dealroom

The Innovative Cellular Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States42.9%
🇨🇳 China42.9%
🇨🇦 Canada14.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Innovative Cellular Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Innovative Cellular Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.